<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00059995</url>
  </required_header>
  <id_info>
    <org_study_id>MDX-060-01</org_study_id>
    <secondary_id>MSKCC-02121</secondary_id>
    <secondary_id>CDR0000298995</secondary_id>
    <nct_id>NCT00059995</nct_id>
  </id_info>
  <brief_title>MDX-060 Monoclonal Antibody in Treating Patients With Refractory or Relapsed Lymphoma</brief_title>
  <official_title>Phase I/II Open Label, Dose-Escalating Study of MDX-060 Administered Weekly for 4 Weeks in Patients With Refractory/Relapsed CD30 Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies such as MDX-060 can locate cancer cells and either kill them&#xD;
      or deliver cancer-killing substances to them without harming normal cells.&#xD;
&#xD;
      PURPOSE: Phase I/II trial to study the effectiveness of MDX-060 monoclonal antibody in&#xD;
      treating patients who have refractory or relapsed lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the safety and tolerability of MDX-060 monoclonal antibody in patients with&#xD;
           refractory or relapsed CD30-positive lymphoma.&#xD;
&#xD;
        -  Determine the maximum tolerated dose and dose-limiting toxicity of this drug in these&#xD;
           patients.&#xD;
&#xD;
        -  Determine the pharmacokinetic profile of this drug in these patients.&#xD;
&#xD;
        -  Determine, preliminarily, the efficacy (antilymphoma activity) of this drug in these&#xD;
           patients.&#xD;
&#xD;
      OUTLINE: This is an open-label, multicenter, dose-escalation study.&#xD;
&#xD;
      Patients receive MDX-060 monoclonal antibody IV over 90 minutes once weekly for 4 weeks.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of MDX-060 monoclonal antibody until the&#xD;
      maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at&#xD;
      which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is&#xD;
      determined, an additional 16 patients are accrued and receive MDX-060 monoclonal antibody at&#xD;
      the MTD.&#xD;
&#xD;
      Patients are followed monthly for 3 months and then every 3 months for 18 months or until&#xD;
      disease progression.&#xD;
&#xD;
      PROJECTED ACCRUAL: A maximum of 40 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2003</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>iratumumab</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed B-cell or T-cell lymphoma&#xD;
&#xD;
               -  Hodgkin's lymphoma and anaplastic large cell lymphoma eligible&#xD;
&#xD;
               -  No HIV-associated lymphoma&#xD;
&#xD;
          -  CD30-positive disease by biopsy, flow cytometry, or immunohistochemistry&#xD;
&#xD;
               -  At least 50% of malignant cells (specifically Reed-Sternberg cells for Hodgkin's&#xD;
                  lymphoma) must express CD30&#xD;
&#xD;
          -  Must meet one of the following criteria for relapsed/refractory disease:&#xD;
&#xD;
               -  Relapsed after prior chemotherapy or radiotherapy and autologous or allogeneic&#xD;
                  bone marrow transplantation (if appropriate)&#xD;
&#xD;
                    -  Relapsed disease must be within the prior irradiated field&#xD;
&#xD;
               -  Disease that is refractory to prior chemotherapy or radiotherapy with no other&#xD;
                  curative treatment option&#xD;
&#xD;
                    -  Disease progression must be within the prior irradiated field&#xD;
&#xD;
          -  Progressive and evaluable disease (measurable disease required for patients accrued on&#xD;
             study after the maximum tolerated dose is determined)&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  Over 12&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 12 weeks&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  WBC at least 1,500/mm^3*&#xD;
&#xD;
          -  Neutrophil count at least 1,000/mm^3*&#xD;
&#xD;
          -  Platelet count at least 75,000/mm^3*&#xD;
&#xD;
          -  Hemoglobin at least 8.0 g/dL* NOTE: *Laboratory abnormalities attributable to organ&#xD;
             involvement by lymphoma are allowed&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  AST no greater than 2 times upper limit of normal (ULN)*&#xD;
&#xD;
          -  Bilirubin no greater than 2.0 mg/dL (unless due to Gilbert's syndrome)*&#xD;
&#xD;
          -  Hepatitis B surface antigen negative&#xD;
&#xD;
          -  Hepatitis C antibody negative NOTE: *Laboratory abnormalities attributable to organ&#xD;
             involvement by lymphoma are allowed&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than 2 times ULN* NOTE: *Laboratory abnormalities attributable&#xD;
             to organ involvement by lymphoma are allowed&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective barrier contraception during and for 9 months&#xD;
             after study participation&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No other active malignancy within the past 5 years except basal cell or squamous cell&#xD;
             skin cancer or carcinoma in situ of the cervix&#xD;
&#xD;
          -  No active significant infection&#xD;
&#xD;
          -  No apparent opportunistic infection, as indicated by any of the following:&#xD;
&#xD;
               -  Purified protein derivative recently determined to be positive&#xD;
&#xD;
               -  Infectious infiltrate by chest x-ray&#xD;
&#xD;
               -  Recent changes in fever/chill patterns&#xD;
&#xD;
               -  New, unexplained neurological symptoms&#xD;
&#xD;
          -  No underlying medical condition that would preclude receiving study therapy&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior anti-CD30 antibody therapy&#xD;
&#xD;
          -  No other concurrent biologic therapy&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy&#xD;
&#xD;
          -  No concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  No concurrent systemic steroidal therapy (excluding physiologic doses)&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven M. Horwitz, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic Cancer Center</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210-1240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Ansell SM, Horwitz SM, Engert A, Khan KD, Lin T, Strair R, Keler T, Graziano R, Blanset D, Yellin M, Fischkoff S, Assad A, Borchmann P. Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. J Clin Oncol. 2007 Jul 1;25(19):2764-9. Epub 2007 May 21.</citation>
    <PMID>17515574</PMID>
  </results_reference>
  <verification_date>November 2009</verification_date>
  <study_first_submitted>May 6, 2003</study_first_submitted>
  <study_first_submitted_qc>May 6, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2003</study_first_posted>
  <last_update_submitted>May 29, 2013</last_update_submitted>
  <last_update_submitted_qc>May 29, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 30, 2013</last_update_posted>
  <keyword>recurrent adult Hodgkin lymphoma</keyword>
  <keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
  <keyword>anaplastic large cell lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent childhood large cell lymphoma</keyword>
  <keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

